April 01, 2026

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-...

The ASCO Post

March 31, 2026

Advancing Precision Oncology: What Pooled Trial Data Reveal About 177 Lu-PSMA-617 in mCRPC

Radiopharmaceutical therapy is rapidly reshaping the treatment landscape for advanced prostate cancer.

Baptist Health South Florida

March 30, 2026

Side Effects: Variety Is Overrated

The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.

Conexiant

March 30, 2026

GlycoRNA Comes into Focus with Mass Spectrometry Blueprint

New review maps analytical workflows to decode a surprising class of sugar-coated RNA

The Analytical Scientist

March 30, 2026

New Frontiers in Neuroendocrine Tumors: Enhancing Diagnosis, Treatment, and Patient Outcomes

Explore the latest advancements in diagnosing and treating neuroendocrine tumors as discussed by Paula S. Kennedy-Newton at JADPRO Live 2025.

JADPRO

March 26, 2026

AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?

The promise of artificial intelligence (AI) technologies to provide highly personalized oncology care for patients and improve outcomes has been decades in the making. In a 1987 editorial in The New E...

The ASCO Post

March 26, 2026

Obesity’s Cancer Role Underestimated

A proposed framework highlights potential sources of bias in current estimates

Conexiant

March 26, 2026

Roswell Park Faculty to Present at National Comprehensive Cancer Network 2026 Annual Conference

Clinical researchers from Roswell Park Comprehensive Cancer Center are among the experts invited to share insights and clinical best practices at the National Comprehensive Cancer Network (NCCN) 2026 Annual Conference March 27-29 in Orlando, Florida.

Roswell Park Comprehensive Cancer Center

March 24, 2026

Low-Dose PFAS Exposure Alters Cellular Metabolism 

Cell culture model reveals lipid remodeling and oxidative stress following prolonged PFAS exposure 

The Analytical Scientist

March 24, 2026

Stanford Names Leader for Drug Development and Precision Oncology

Vivek Subbiah, MD, has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. In thi...

The ASCO Post